Attention: All Pharmacy Providers – Delaware State Medicaid Pharmacy Policies Related to Coronavirus Disease 2019

On March 24th, 2020, the Delaware Division of Professional Regulation issued a letter to healthcare providers detailing shortages of hydroxychloroquine and chloroquine due to improper prescribing of these drugs for prophylaxis for COVID-19. The full text of this letter is available here: Hydroxychloroquine and Chloroquine Supply Issues.

On March 30th, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for use of these medications in hospitalized patients only with COVID-19. This is based on limited in-vitro and anecdotal data. Full details of that EUA are here: FDA EUA Letter.

Hydroxychloroquine is FDA-approved and widely used for treatment of chronic diseases like lupus and rheumatoid arthritis. DMMA recognizes the importance of maintaining adequate supplies of this medication for patients with those chronic diseases and the lack of evidence of efficacy of hydroxychloroquine and chloroquine for COVID-19 in outpatient settings. DMMA will not be covering the use of these medications for outpatients except for FDA-approved indications.

Effective 3/31/2020, Delaware Medicaid is changing the status of all hydroxychloroquine and chloroquine NDCs to require prior authorization. Patients previously established on the medication, as evidenced by a paid claim within the previous 120 days, will be grandfathered in the system to avoid any interruptions. All new prescriptions must have a valid diagnosis code with them. Only FDA-approved diagnosis codes will qualify for payment per Medicaid policy: 34-day supply or 100 units—whichever is greater is allowed.

Need any further Assistance?

- Please reach out to the Pharmacy Services Team at 1-800-999-3371 option 0, option 1